Real world data regarding the management of cancer-associated thrombosis
AffiliationDepartment of Oncology, 401 Military Hospital of Athens, Athens.
MetadataShow full item record
AbstractPurpose of review: Patients with cancer are at high risk for thrombotic events, mainly deep vein thrombosis and pulmonary embolism. Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the current treatment options for cancer-associated thrombosis (CAT). We assessed real world data (RWD) regarding treatment patterns of CAT from 1 September 2018 to 31 January 2020. Recent findings: RWD showed that LMWHs were the most common initial anticoagulation treatment for CAT. Based on these data DOACs had a lower risk of recurrent venous thromboembolism compared with LMWHs and warfarin. However, the selection bias and the small number of patients in these studies might explain this difference and these limitations should be taken into consideration. Moreover, there was no statistical difference regarding adverse events during anticoagulant treatment between LMWHs and DOACs with the limitations of RWD. As far as the duration of the treatment is concerned, the adherence ranged from 100% to 67.3% at 6 months. Summary: The current review of RWD illustrates that LMWHs and DOACs are used for the treatment of CAT. LMWHs are most commonly used for the initial management of CAT. Data regarding recurrence of CAT, adverse events, compliance and duration of anticoagulant treatment should be analyzed with caution as RWD are observational studies with many limitations. Further research is needed to elucidate the best algorithm for the management of CAT.
CitationTsoukalas N, Tsapakidis K, Galanopoulos M, Karamitrousis E, Kamposioras K, Tolia M. Real world data regarding the management of cancer-associated thrombosis. Curr Opin Oncol. 2020;32(4):289-94.
JournalCurrent Opinion in Oncology
- Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
- Authors: Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akl EA
- Issue date: 2018 Jun 19
- Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
- Authors: Vedovati MC, Giustozzi M, Bonitta G, Agnelli G, Becattini C
- Issue date: 2018 Oct
- Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials.
- Authors: Gu ZC, Yan YD, Yang SY, Shen L, Kong LC, Zhang C, Wei AH, Li Z, Wang XH, Lin HW
- Issue date: 2020 Feb
- Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States.
- Authors: Guo JD, Hlavacek P, Poretta T, Wygant G, Lane D, Gorritz M, Wang X, Chen CC, Wade RL, Pan X, Rajpura J, Stwalley B, Rosenblatt L
- Issue date: 2020 Aug
- Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
- Authors: Li A, Garcia DA, Lyman GH, Carrier M
- Issue date: 2019 Jan